4D Molecular Therapeutics Inc (NAS:FDMT)
$ 25.15 0 (0%) Market Cap: 1.30 Bil Enterprise Value: 788.60 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 57/100

4D Molecular Therapeutics Inc 4D-150 Phase 2 PRISM Clinical Data Call Transcript

Feb 05, 2024 / 01:00PM GMT
Release Date Price: $32.29 (+84.62%)
Operator

Ladies and gentlemen, thank you for standing by and welcome to 4D Molecular Therapeutics webcast presentation of interim data from the 4D-150 Phase 2 PRISM dose expansion cohort in wet AMD patients with severe disease activity and high treatment burden. (Operator Instructions)

As a reminder, today's call is being recorded. With that, I will hand the call over to Uneek Mehra, Chief Financial and Business Officer, who will make introductory comments.

Uneek Mehra
4D Molecular Therapeutics Inc - Chief Financial and Business Officer, Principal Financial and Accounting Officer

Thank you, operator, and welcome to our webcast. We issued a press release describing the 4D-150 PRISM clinical trial interim results on Saturday, February 3. And the recording of this webcast will be accessible in the Investors section of the 4DMT website after the completion of this call today.

With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer; Dr. Bob Kim, our Chief Medical Officer; and Dr. Arshad Khanani from Sierra Eye Associates and a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot